PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Abdallah FlaifelWanling XieDavid A BraunMiriam FicialZiad BakounyAmin H NassarRebecca B JenningsBernard EscudierDaniel J GeorgeRobert J MotzerMichael J MorrisThomas PowlesEvelyn WangYing HuangGordon J FreemanToni K ChoueiriSabina SignorettiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Higher PD-L1 expression results in worse clinical outcomes in mRCC treated with targeted therapy. Furthermore, PD-L1 expression is not predictive of response to cabozantinib therapy.